Ionis Pharmaceuticals (IONS) Cash from Investing Activities (2009 - 2026)

Ionis Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at $536.8 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 214.93% year-over-year to $536.8 million in Q1 2026; TTM through Mar 2026 was $88.6 million, a 323.29% increase from a year earlier, with the FY2025 full-year figure at -$277.8 million, down 107.25% from the prior year.
• Cash from Investing Activities rose to $536.8 million in Q1 2026 per IONS's latest filing, from -$419.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $536.8 million in Q1 2026 and bottomed at -$419.5 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is $62.4 million (2024), against an average of -$20.7 million.
• Across the five-year window, Cash from Investing Activities surged 2203.96% in 2023 and slumped 714.99% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $212.1 million in 2022, then sank by 112.59% to -$26.7 million in 2023, then surged by 355.36% to $68.2 million in 2024, then slumped by 714.99% to -$419.5 million in 2025, then soared by 227.97% to $536.8 million in 2026.
• Per Business Quant, the three latest IONS Cash from Investing Activities figures stand at $536.8 million (Q1 2026), -$419.5 million (Q4 2025), and $91.3 million (Q3 2025).